K Number
K221083
Device Name
Smartlux Mini
Manufacturer
Date Cleared
2022-07-12

(90 days)

Product Code
Regulation Number
878.4810
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

Blue (415-425mm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

Red (630-640nm) and Infrared (820-830mm) Combination is intended to emit energy in the red and infrared region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Combination of Infrared (820-830nm) and Yellow (585-595nm) is intended to emit energy in the IR and visible spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

Device Description

The Photo-Therapy Device SMARTLUX MINI is a portable device which uses specific wavelengths of light, produced by light emitting diodes (LEDs).

The device produces light in the following regions of the light spectrum:

  • · Red (630-640nm)
  • · Blue (415-425nm)
  • · Yellow (585-595nm)
  • Infra-red (820-830nm)

This device's main components are the stand, the head, color touch screen, and the power supply. User interface software allows the operator to access and control all device functions.

AI/ML Overview

The provided text is a 510(k) summary for the Smartlux Mini device, which is a phototherapy unit. It details the device's characteristics and its substantial equivalence to a predicate device (Soli-Lite LG4 Galileo). However, it does not contain information about clinical studies with acceptance criteria or performance metrics related to diagnostic accuracy, sensitivity, specificity, or reader studies.

The document primarily focuses on:

  • Non-Clinical Testing: Conformance to electrical safety, electromagnetic compatibility, and performance standards (e.g., IEC 60601-1, IEC 60601-1-2, IEC 60601-2-57, IEC 62471).
  • Software Validation: The software was designed, developed, verified, and validated according to a software development process, and is considered a "MODERATE level of concern software."
  • Technological Equivalence: Comparison of wavelengths, irradiance, and operation modes to a predicate device (K192755).

Therefore, I cannot provide a table of acceptance criteria and reported device performance related to clinical efficacy or diagnostic performance, nor can I answer questions about sample sizes for test/training sets, expert ground truth establishment, adjudication methods, or MRMC studies, as this information is not present in the provided document.

The document states that "Testing of key performance characteristics demonstrates that the subject device can be used safely and effectively for the proposed indications for use," but it does not elaborate on what these "key performance characteristics" are in terms of clinical outcomes or how effectiveness was quantitatively demonstrated by such testing, beyond the non-clinical testing listed.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains two logos. On the left is the Department of Health & Human Services logo. On the right is the FDA logo, which includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

July 12, 2022

MEDMIX Co., Ltd. % Jonghyun Kim Chief Consultant GMS Consulting 4th Floor, Digital Cube, 34, Sangamsan-ro Seoul, Mapo-gu 03909 Korea, South

Re: K221083

Trade/Device Name: Smartlux Mini Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX, ILY Dated: April 11, 2022 Received: April 13, 2022

Dear Jonghyun Kim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Jianting Wang Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K221083

Device Name SMARTLUX MINI

Indications for Use (Describe)

Blue (415-425mm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

Red (630-640nm) and Infrared (820-830mm) Combination is intended to emit energy in the red and infrared region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Combination of Infrared (820-830nm) and Yellow (585-595nm) is intended to emit energy in the IR and visible spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

Type of Use (Select one or both, as applicable)
-------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

[As Required by 21 CFR 807.92]

1. Date Prepared [21 CFR 807.92(a)(a)]

April 11, 2022

2. Submitter's Information [21 CFR 807.92(a)(1)]

  • Name of Manufacturer: MEDMIX Co., Ltd
  • Address: B-707 Smartvalley, 30, Songdomirae-ro, Yeonsu-gu, Incheon, Republic of Korea ● Contact Name: Yunseok Yu ● Telephone No.: +82 10-9487-8160 ● Email Address: ysyu@medmix.co.kr ● Registration No.: K221083

3. Trade Name, Common Name, Classification [21 CFR 807.92(a)(2)]

510(k) NumberK221083
Trade/Device/Model NameSMARTLUX MINI
Product NamePhototherapy Unit
Device Classification NamePowered Laser Surgical Instrument
Regulation Number21 CFR 878.4810 / 21 CFR 890.5500
Classification Product CodeGEX (Primary), ILY (Secondary)
Device Class2
510(k) Review PanelGeneral & Plastic Surgery / Physical Medicine

{4}------------------------------------------------

4. Identification of Predicate Device(s) [21 CFR 807.92(a)(3)]

The identified predicate device within this submission is shown as follow;

Predicate Device

510(k) NumberK192755
Trade/Device/Model NameSoli-Lite LG4 Galileo
Product NamePhototherapy Unit
Device Classification NamePowered Laser Surgical Instrument
Regulation Number21 CFR 878.4810 / 21 CFR 890.5500
Classification Product CodeGEX (Primary), ILY (Secondary)
Device Class2
510(k) Review PanelGeneral & Plastic Surgery / Physical Medicine

{5}------------------------------------------------

5. Description of the Device [21 CFR 807.92(a)(4)]

The Photo-Therapy Device SMARTLUX MINI is a portable device which uses specific wavelengths of light, produced by light emitting diodes (LEDs).

The device produces light in the following regions of the light spectrum:

  • · Red (630-640nm)
  • · Blue (415-425nm)
  • · Yellow (585-595nm)
  • Infra-red (820-830nm)

This device's main components are the stand, the head, color touch screen, and the power supply. User interface software allows the operator to access and control all device functions.

6. Indications for use [21 CFR 807.92(a)(5)]

Blue (415-425nm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

Red (630-640nm) and Infrared (820-830nm) Combination is intended to emit energy in the red and infrared region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Combination of Infrared (820-830nm) and Yellow (585-595nm) is intended to emit energy in the IR and visible spectrum to provide topical heatinq for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

{6}------------------------------------------------

7. Technological Characteristics (Equivalence to Predicate Device) [21 CFR 807.92(a)(6)]

Provided below is a table summarizing and comparing the technological characteristics of the SMARTLUX MINI and the predicate device:

Subject DevicePredicate Device
Product NamePhototherapy UnitPhototherapy Unit
Model NameSMARTLUX MINISoli-Lite LG4 Galileo
ManufacturerMEDMIX Co., Ltd.Silhouet-Tone Corporation
Indications for UseBlue (415-425nm), is generally indicated to treat dermatologicalconditions and specifically indicated totreat moderate inflammatory acnevulgaris.Red (630-640nm) and Infrared (820-830nm) Combination is intended toemit energy in the red and infraredregion of the spectrum for use indermatology for the treatment ofperiorbital wrinkles.Combination of Infrared (820-830nm)and Yellow (585-595nm) is intendedto emit energy in the IR and visiblespectrum to provide topical heatingfor the purpose of elevating tissuetemperature; for the temporary reliefof minor muscle and joint pain,arthritis and muscle spasm; relievingstiffness; promoting the relaxation ofmuscle tissue; and to temporarilyincrease local blood circulation whereapplied.Blue (410-415nm), is generally indicated to treat dermatologicalconditions and specifically indicated totreat moderate inflammatory acnevulgaris.Red (620-633nm) and Infrared (820-830nm) Combination is intended toemit energy in the red and infra-redregion of the spectrum for use indermatology for the treatment ofperiorbital wrinkles.Combination of Infrared (820- 830nm)and Yellow (585-595nm) is intendedto emit energy in the IR and visiblespectrum to provide topical heatingfor the purpose of elevating tissuetemperature; for the temporary reliefof minor muscle and joint pain,arthritis and muscle spasm; relievingstiffness; promoting the relaxation ofmuscle tissue; and to temporarilyincrease local blood circulation whereapplied.
SubmissionNumberK221083K192755
Product CodeGEX (Primary), ILY (Secondary)GEX (Primary), ILY (Secondary)
Device Class22
ConfigurationPortablePortable
ComponentsStand, Head, Color touch screen,Power supplierMain frame, irradiator, lifting stand
WavelengthRED 630-640nmBLUE 415-425nmIR: 820-830nmYELLOW: 585-595nmRed 620-633nmBlue 410-415nmIR 820-830nm / Yellow 585- 595nm
EffectiveirradianceAdjustable 5 levelsRed : 26-50 mW/cm2Blue : 941 mW/cm2Yellow: 12-20 mW/cm2IR: 1128 mW/cm2Adjustable 4 levelsRed: 19-47mW/cm2Blue: 25-40mW/cm2IR/Yellow: 29-61mW/cm2
OperationinterfaceContinuous operationContinuous operation
Subject DevicePredicate Device
Operation modeIEC 60601-1IEC 60601-1-2IEC 60601-2-57IEC 62471IEC 60601-1IEC 60601-1-2IEC 60601-2-57IEC 62471
MicroprocessorcontrolYesYes
Continuous/PulsedOutputContinuous and Pulsed (up to 500 pulsesper second)Continuous

{7}------------------------------------------------

The proposed device, SMARTLUX MINI has been tested about electrical safety, EMC, and performance, and the software has been validated. Differences and Risks associated with that:

  • · The components of the subject device have similar composition as the components of the predicate device This difference does not influence the effectiveness and safety of product.
  • • The wavelengths and intensities emitted from subject device are similar to the wavelengths and intensities emitted by the predicate device. The predicate device emits light continuously during its treatment cycles. The SMARTLUX MINI also emits light continuously but it also has the option of emitting 50% duty cycle pulses at up to 500 times per second. This difference does not influence the effectiveness and safety of product.

{8}------------------------------------------------

8. Non-Clinical Test summary

The SMARTLUX MINI conforms with voluntary standards for electrical safety, electromagnetic compatibility. The following data were provided in support of the substantial equivalence determination:

  1. Electrical Safety, Electromagnetic Compatibility and Performance:

The SMARTLUX MINI conforms with the electrical safety and electromagnetic compatibility requirements established by the standards.

StandardsNo.StandardsOrganizationStandard TitleVersionPublicationYear
ES60601-1AAMI ANSIMedical Electrical Equipment - Part 1: GeneralRequirements for Basic Safety and EssentialPerformance (IEC 60601-1:2005, MOD)ES60601-1:2005(R)2012 andA1:20122014
60601-1-2IECMedical Electrical Equipment - Part 1-2:General Requirements for Safety - CollateralStandard: Electromagnetic Compatibility -Requirements and Tests60601-1-2Edition 4.02014-022016
60601-2-57IECMedical Electrical Equipment - Part 2-57:Particular requirements for the basic safetyand essential performance of non-laser lightsource equipment intended for therapeutic,diagnostic, monitoring and cosmetic/aestheticuse60601-2-57Edition 1.02011-012012
62471IECPhotobiological safety of lamps and lampsystemsIEC 62471First edition2006-072012

2) Software Validation

The SMARTLUX MINI contains MODERATE level of concern software. The software was designed and developed according to a software development process and was verified and validated. Software information is provided in accordance with FDA quidance:

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005).

{9}------------------------------------------------

9. Conclusion [21 CFR 807.92(b)(3)]

The SmartLux Mini light-emitting device that is the subject of this premarket notification uses similar technology and emits wavelengths and intensities of light that are similar to the predicate K192755. Testing of key performance characteristics demonstrates that the subject device can be used safely and effectively for the proposed indications for use. The Smartlux Mini light emitting device is considered to be substantially equivalent to the predicate device K192755.

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.